NASDAQ$TYRA
Tyra Biosciences Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2023 and highlighted recent corporate progress.
Tyra Biosciences reported a net loss of $13.3 million for the second quarter of 2023 and had cash and cash equivalents of $232.4 million as of June 30, 2023. The company is advancing its pipeline, including TYRA-300 and TYRA-200, and received Orphan Drug Designation for TYRA-300 in achondroplasia.
- Granted Orphan Drug Designation from U.S. FDA for Achondroplasia for TYRA-300.
- SURF301 Phase 1/2 oncology study remains on target with ongoing enrollment in Part B.
- TYRA-200 Phase 1 study on track with first patient expected to be dosed in 2H 2023.
- Held a strong cash position of $232.4 million as of Q2 2023.
Headline financials
Revenue & EPS history
Tyra Biosciences · Revenue · Quarterly
$0
Forward guidance
TYRA cautions that statements contained in the press release regarding matters that are not historical facts are forward-looking statements and are based on current beliefs and expectations.
Tailwinds
- Potential to develop next-generation precision medicines
- Potential safety and therapeutic benefits of TYRA-300 and other product candidates
- Potential for TYRA-300 to become a best-in-class agent
- Expected timing and phase of clinical development of TYRA-300 and TYRA-200
- Potential for SNÅP to develop therapies in targeted oncology and genetically defined conditions
Headwinds
- Early in development efforts, approach to drug discovery is novel and unproven.
- Potential delays in commencement, enrollment, and completion of preclinical studies and clinical trials
- Results from preclinical studies or early clinical trials not necessarily being predictive of future results
- Dependence on third parties in connection with manufacturing, research and preclinical testing
- Unexpected adverse side effects or inadequate efficacy of product candidates
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2023
+2.0%
Avg return
Earnings day
+3.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
50%
9 / 18 earnings
Positive
+29.8%
Q3 2021
Best reaction
-11.5%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.5% | +7.7% | +21.8% | |
| Q3 2025 | +0.3% | +8.4% | +50.6% | |
| Q2 2025 | +0.4% | -4.3% | +17.0% | |
| Q1 2025 | -3.1% | -4.0% | +2.3% | |
| Q4 2024 | -0.8% | -10.5% | +3.9% | |
| Q3 2024 | -5.9% | -6.9% | -8.1% | |
| Q1 2024 | -3.8% | +3.1% | +9.7% | |
| Q4 2023 | +7.0% | +3.0% | -9.7% | |
| Q3 2023 | -6.3% | -8.1% | +2.5% | |
| Q2 2023 | +0.9% | +1.6% | -3.4% | |
| Q1 2023 | -3.3% | +7.0% | +13.1% | |
| Q4 2022 | -3.3% | +0.0% | -9.8% | |
| Q3 2022 | -7.1% | +12.9% | -3.1% | |
| Q2 2022 | +11.1% | +14.7% | -24.0% | |
| Q1 2022 | +0.1% | -5.9% | -17.8% | |
| Q4 2021 | -11.5% | -5.3% | -6.4% | |
| Q2 2021 | +29.8% | +20.3% | -26.6% | |
| Q3 2021 | +29.8% | +20.3% | -26.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro